ArticleBMC medical research methodology2018
An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use.
Article in BMC medical research methodology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Hazard Ratios and Alternative Effect Measures: An Applied Illustration.Pharmacoepidemiology and drug safety · 2024Review
- Injurious Fall Risk Differences Among Older Adults With First-Line Depression Treatments.JAMA network open · 2024Article
- Weighing risks and benefits in the presence of competing risks.Current epidemiology reports · 2023Article
- Alcohol use and the longitudinal HIV care continuum for people with HIV who enrolled in care between 2011 and 2019.Annals of epidemiology · 2023Article
- Estimating causal effects in the presence of competing events using regression standardisation with the Stata command standsurv.BMC medical research methodology · 2022Article
- A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing.Medical decision making : an international journal of the Society for Medical Decision Making · 2022Article
- Restricted Mean Survival Time for Survival Analysis: A Quick Guide for Clinical Researchers.Korean journal of radiology · 2022Article
- Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA.Breast cancer research and treatment · 2022Article
- Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data.Computational and mathematical methods in medicine · 2022Article
- Stratified Restricted Mean Survival Time Model for Marginal Causal Effect in Observational Survival Data.Annals of epidemiology · 2021Article
- Estimation and modeling of the restricted mean time lost in the presence of competing risks.Statistics in medicine · 2021Article
- Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models.BMC medical research methodology · 2021Article
- Optimal two-stage designs based on restricted mean survival time for a single-arm study.Contemporary clinical trials communications · 2021Article
- The use of restricted mean time lost under competing risks data.BMC medical research methodology · 2020Article
- Limitations of the UNAIDS 90-90-90 metrics: a simulation-based comparison of cross-sectional and longitudinal metrics for the HIV care continuum.AIDS (London, England) · 2020Article
- Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times: Application in the Framingham Heart Study Community-Based Cohort.Circulation. Cardiovascular quality and outcomes · 2020Observational
- Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas.Systematic reviews · 2019Article
- Incidence of autoimmune pulmonary alveolar proteinosis estimated using Poisson distribution.ERJ open research · 2019Article
- Summarizing and communicating on survival data according to the audience: a tutorial on different measures illustrated with population-based cancer registry data.Clinical epidemiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRestricted mean survival time (RMST) is an underutilized estimand in time-to-event analyses. Herein, we highlight its strengths by comparing time to (1) all-cause mortality and (2) initiation of antiretroviral therapy (ART) for HIV-infected persons who inject drugs (PWID) and persons who do not inject drugs.
methodsRMST to death was determined by integrating the Kaplan-Meier survival curve to 5 years of follow-up. To account for the competing risks of death and loss-to-clinic when estimating time to ART, we calculated RMST to ART initiation by estimating the area between the survival curve for ART initiation and the cumulative incidence curve for death or loss-to-clinic. We standardized all curves using inverse probability of exposure weights.
resultsWe followed 3044 HIV-positive, ART-naive persons from enrollment into the Johns Hopkins HIV Clinical Cohort from 1996 to 2014. PWID had a - 0.19 year (95% confidence interval (CI): - 0.29, - 0.10) difference in survival over 5 years of follow-up compared to persons who did not inject drugs. There was no difference between the two groups in time not on ART while alive and in clinic (RMST difference = 0.08, 95% CI: -0.10, 0.36).
conclusionsPWID have similar expected time to ART initiation after properly accounting for their greater risk of death and loss-to-clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.